Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Transcript

Impact · against what's priced in

Xencor's presentation of initial Phase I dose escalation results for XmAb819 in renal cell carcinoma provides a data update on its pipeline. While the presentation of results is a positive step in clinical development, the initial nature of the dose escalation data lacks the efficacy signals required to significantly re-rate the stock.

XNCR+0.10

No priced-in read yet